Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evolus, Inc. (EOLS)

Evolus expands Symatese license to Canada, Australia and New Zealand for Estyme

Neutral Impact 3 of 5 product/contract Written later

Evolus Europe amended its December 20, 2023 license and distribution agreement with Symatese Aesthetics, adding Canada and Australia/New Zealand as territories and granting Evolus exclusive rights to commercialize the Estyme injectable hyaluronic acid gel line there. The filing gives Evolus payments of €920,000 upfront and up to an additional €1.38 million on regulatory approvals, with commercialization expected in 2028, so the financial commitment is modest and the effect on results depends on approvals and sales that are not yet quantified.

Key points

  • Upfront signing payments of €920,000, plus up to €1.38 million more on receipt of certain regulatory approvals
  • Initial term of 15 years for each new territory from first regulatory approval, with automatic five-year renewals
  • Symatese is responsible, at its expense, for development and regulatory work needed in the new territories
  • Commercialization in Canada, Australia and New Zealand is expected in 2028; the company cites a total addressable market of about $500 million annually for neurotoxins and dermal fillers in these markets

The filing

CompanyEvolus, Inc. (EOLS)
Form8-K, current report
Filed with the SECAug 4, 2026, 8:46 AM ET
Accession number0001570562-26-000083

Items reported: 1.01 Material Definitive Agreement7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.